Cost and outcome in stem cell collections in HLA-haplo identical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized blood and bone marrow for patients with hematologic malignancies

Transfusion and Apheresis Science

Volumn 43, Issue 1, 2010, Pages 23-28

  Chen, Xing Hua ^a   Zhang, Cheng ^a   Zhang, Xi ^a   Gao, Li ^a   Gao, Lei ^a   Kong, Pei Yan ^a   Peng, Xian Gui ^a   Sun, Ai Hua ^a   Zeng, Dong Feng ^a   Wang, Qing Yu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow; Cost; Granulocyte colony stimulating factor; HLA haplo identical mismatched related transplantation; Outcome; Peripheral blood stem cells; Stem cells collection

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; BONE MARROW; BONE PAIN; CD34 SELECTION; CELL COUNT; COST; FEMALE; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; HUMAN EXPERIMENT; MALE; MUSCLE CRAMP; MYALGIA; NORMAL HUMAN; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL BLOOD STEM CELL; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

ADULT; BLOOD DONORS; BONE MARROW TRANSPLANTATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; MALE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77955423178     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.05.003     Document Type: Article

References (41)

1. Koh L.P., Chao N.J. Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review. Blood cells Mol Dis 2008, 40(1):20-24.
2. Chen X.H., Zhang C., Zhang X., et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009, 15(2):266-273.
3. Bishop M.R., Henslee-Downey P.J., Anderson J.R., et al. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone marrow transplant 1996, 18(4):747-753.
4. Schattenberg A.V., Dolstra H. Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Curr opin oncol 2005, 17(6):617-621.
5. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
6. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110(7):2764-2767.
7. Aggarwal S., Pittinger M.F. Human mesenchymal stem cells modulate alloantigen immune cell responses. Blood 2005, 105(4):1815-1822.
8. Tatsumi K., Otani H., Sato D., et al. Granulocyte-colony stimulating factor increases donor mesenchymal stem cells in bone marrow and their mobilization into peripheral circulation but does not repair dystrophic heart after bone marrow transplantation. Circ J 2008, 72(8):1351-1358.
9. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000, 26(4):397-404.
10. Wang T.F., Wen S.H., Chen R.L., et al. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant 2008, 14(11):1305-1311.
11. Zhang C., Chen X., Zhang X., et al. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematologic malignancies: influence of disease, mobilization method, age and sex. Transfus Apher Sci 2008, 39(1):21-28.
12. Davies S.M., Kollman C., Anasetti C., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000, 96(13):4096-4102.
13. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000, 95(7):2219-2225.
14. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 2000, 14(3):502-504.
15. Sierra J., Storer B., Hansen J.A., et al. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997, 89(11):4226-4235.
16. Aversa F., Velardi A., Tabilio A., et al. Haploidentical stem cell transplantation in leukemia. Blood Rev 2001, 15(3):111-119.
17. Aversa F., Reisner Y., Martelli M.F. The haploidentical option for high-risk haematological malignancies. Blood cells Mol Dis 2008, 40(1):8-12.
18. Passweg J.R. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2006, 19(4):811-824.
19. Huang X.J., Chang Y.J., Zhao X.Y. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primedbone marrow grafts in different proportions. Transplant Immunol 2007, 17(3):193-197.
20. Lu D.P., Dong L.J., Wu T., et al. Conditioning including antithymocyte HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA identical sibling transplantation. Blood 2006, 107(8):3065-3073.
21. Huang X.J., Han W., Xu L.P., et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chinese Medical J 2004, 117(12):1778-1785.
22. + cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007, 13(12):1515-1524.
23. Chen X.H., Gao L., Zhang X., et al. HLA-haploidentical blood and marrow transplantation with antithymocyte globulin: Long-term outcome compared with HLA-identical sibling transplantation. Blood Cells Mol Dis 2009, 43(1):98-104.
24. De la Rubia J., Arbona C., de Arriba F., et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002, 42(1):4-9.
25. Moncada V., Bolan C., Yau Y., et al. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003, 43(4):495-501.
26. + cell yields in G-CSF-induced PBPC mobilization in healthy donors. Transfusion 2004, 44(4):526-532.
27. Suzuya H., Watanabe T., Nakagawa R., et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005, 89(4):229-235.
28. Ings S.J., Balsa C., Leverett D., et al. Peripheral blood stem cell yield in 400 normal donors mobilized with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006, 134(5):517-525.
29. Cassens U., Barth I., Baumann C., et al. Factors affecting the efficacy of peripheral blood progenitor cells collections by large-volume leukapheresis with standardized processing volumes. Transfusion 2004, 44(11):1593-1602.
30. Xing Z., Ryan M.A., Daria D., et al. Increased hematopoietic stem cell mobilization in aged mice. Blood 2006, 108(7):2190-2197.
31. Reddy R.L. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci 2005, 32(1):63-72.
32. Tomblyn M., Gordon L., Singhal S., et al. Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF. Bone Marrow Transplant 2005, 36(8):663-666.
33. Fischer J.C., Frick M., Wassmuth R., et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005, 130(5):740-746.
34. Rhodes B., Anderlini P. Allogeneic peripheral blood stem cell collection as of 2008. Transfus Apher Sci 2008, 38(3):219-227.
35. Anderlini P., Donato M., Chan K.W., et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999, 39(6):555-560.
36. + selected progenitor cells from alternative donors. Br J Haematol 2004, 124(1):72-79.
37. Yang Z., Hall A.G. The financial burden of overweight and obesity among elderly Americans: the dynamics of weight, longevity, and health care cost. Health Serv Res 2008, 43(3):849-868.
38. + cell counts and on the collection of peripheral blood stem cells. Transfusion 1996, 36(7):601-610.
39. Tassi C., Tazzari P.L., Bonifazi F., et al. Short-and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005, 36(4):289-294.
40. Falanga A., Marchetti M., Evangelista V., et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colonystimulating factor. Blood 1999, 93(8):2506-2514.
41. Topcuoglu P., Arat M., Dalva K., et al. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor dependent pathway in healthy donors. Bone Marrow Transplant 2004, 33(2):171-176.